Prediction of sustained response to low-dose pegylated interferon alpha-2b plus ribavirin in patients with genotype 1b and high hepatitis C virus level using viral reduction within 2 weeks after therapy initiation

被引：8

作者：

Tamai, Hideyuki ^{[1
]}

Shingaki, Naoki ^{[1
]}

Shiraki, Tatsuya ^{[1
]}

Tukuda, Hiroshi ^{[1
]}

Mori, Yoshiyuki ^{[1
]}

Moribata, Kosaku ^{[1
]}

Enomoto, Shotaro ^{[1
]}

Deguchi, Hisanobu ^{[1
]}

Ueda, Kazuki ^{[1
]}

Inoue, Izumi ^{[1
]}

Maekita, Takao ^{[1
]}

Iguchi, Mikitaka ^{[1
]}

Yanaoka, Kimihiko ^{[1
]}

Oka, Masashi ^{[1
]}

Ichinose, Masao ^{[1
]}

机构：

[1] Wakayama Med Univ, Dept Internal Med 2, Wakayama 6410012, Japan

来源：

HEPATOLOGY RESEARCH | 2011年 / 41卷 / 12期

关键词：

genotype; 1b; hepatitis C virus core antigen; hepatitis C virus-RNA; high viral load; viral kinetics; PEGINTERFERON ALPHA-2B; COMBINATION THERAPY; VIROLOGICAL RESPONSE; NAIVE PATIENTS; CORE ANTIGEN; ASSOCIATION; INFECTION; LOAD; MANAGEMENT; KINETICS;

D O I：

10.1111/j.1872-034X.2011.00879.x

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Aim: Continuation of pegylated interferon (PEG-IFN) plus ribavirin at the recommended dose is difficult in elderly patients and/or patients with cytopenia or complications. Whether the therapeutic efficacy of low-dose PEG-IFN plus ribavirin therapy could be predicted based on virological response within 2 weeks of therapy initiation was evaluated.

引用

页码：1137 / 1144

页数：8

共 28 条

[1] Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy [J].

Akuta, N ;

Suzuki, F ;

Sezaki, H ;

Suzuki, Y ;

Hosaka, T ;

Someya, T ;

Kobayashi, M ;

Saitoh, S ;

Watahiki, S ;

Sato, J ;

Matsuda, M ;

Kobayashi, M ;

Arase, Y ;

Ikeda, K ;

Kumada, H .

INTERVIROLOGY, 2005, 48 (06) :372-380

[2] Side effects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C [J].

Arase, Yasuji ;

Suzuki, Fumitaka ;

Suzuki, Yoshiyuki ;

Akuta, Norio ;

Kawamura, Yusuke ;

Kobayashi, Masahiro ;

Hosaka, Tetsuya ;

Sezaki, Hitomi ;

Yatsuji, Hiromi ;

Kobayashi, Mariko ;

Ikeda, Kenji ;

Kumada, Hiromitsu .

INTERNAL MEDICINE, 2007, 46 (22) :1827-1832

[3] A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta [J].

Asahina, Y ;

Izumi, N ;

Uchihara, M ;

Noguchi, O ;

Tsuchiya, K ;

Hamano, K ;

Kanazawa, N ;

Itakura, J ;

Miyake, S ;

Sakai, T .

HEPATOLOGY, 2001, 34 (02) :377-384

[4] Peginterferon alpha-2a Is Associated with Higher Sustained Virological Response than Peginterferon alfa-2b in Chronic Hepatitis C: Systematic Review of Randomized Trials [J].

Awad, Tahany ;

Thorlund, Kristian ;

Hauser, Goran ;

Stimac, Davor ;

Mabrouk, Mahasen ;

Gluud, Christian .

HEPATOLOGY, 2010, 51 (04) :1176-1184

[5] Extended treatment duration for hepatitis C virus type 1: Comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin [J].

Berg, T ;

von Wagner, M ;

Nasser, S ;

Sarrazin, C ;

Heintges, T ;

Gerlach, T ;

Buggisch, P ;

Goeser, T ;

Rasenack, J ;

Pape, GR ;

Schmidt, WE ;

Kallinowski, B ;

Klinker, H ;

Spengler, U ;

Martus, P ;

Alshuth, U ;

Zeuzem, S .

GASTROENTEROLOGY, 2006, 130 (04) :1086-1097

[6] Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis [J].

Bertino, Gaetano ;

Ardiri, Annalisa ;

Boemi, Patrizia Maria ;

Calvagno, Giuseppe Stefano ;

Ruggeri, Irene Maria ;

Speranza, Annalisa ;

Santonocito, Maria Milena ;

Ierna, Dario ;

Bruno, Cosimo Marcello ;

Valenti, Maria ;

Boemi, Roberta ;

Naimo, Simona ;

Neri, Sergio .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 66 (10) :1055-1063

[7] Hepatitis C virus core Antigen as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon α-2b plus ribavirin [J].

Buti, M ;

Mendez, C ;

Schaper, M ;

Sauleda, S ;

Valdes, A ;

Rodriguez-Frias, F ;

Jardi, R ;

Esteban, R .

JOURNAL OF HEPATOLOGY, 2004, 40 (03) :527-532

[8] Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin [J].

Buti, M ;

Sanchez-Avila, F ;

Lurie, Y ;

Stalgis, C ;

Valdés, A ;

Martell, M ;

Esteban, R .

HEPATOLOGY, 2002, 35 (04) :930-936

[9] Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C [J].

Davis, GL ;

Wong, JB ;

McHutchison, JG ;

Manns, MP ;

Harvey, J ;

Albrecht, J .

HEPATOLOGY, 2003, 38 (03) :645-652

[10] American Gastroenterological Association medical position statement on the management of hepatitis C [J].

Dienstag, JL ;

McHutchison, JG .

GASTROENTEROLOGY, 2006, 130 (01) :225-230

← 1 2 3 →